Colorectal Cancer Immunotherapy: State of the Art and Future Directions

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699 · see citing works

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989 · see citing works

Safety, activity, and immune correlates of anti–PD-1 antibody in cancer

Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works

A genetic model for colorectal tumorigenesis

Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Comprehensive molecular characterization of human colon and rectal cancer

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

Cancer immunotherapy using checkpoint blockade

Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791 · see citing works

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 2× · see citing works

The consensus molecular subtypes of colorectal cancer

Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170 · see citing works

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · see citing works

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodrı́guez-Bigas, M. A., Fodde, R., Ranzani, G. N., et al. (1998) · PubMed · Cited by 4,087 · see citing works

Colorectal cancer statistics, 2023

Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,907 · see citing works

Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy

Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · see citing works

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · see citing works

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · cited 1× · see citing works

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · see citing works

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088 · see citing works

Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · see citing works

Genomic instability — an evolving hallmark of cancer

Negrini, S., Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2858 · Cited by 2,397 · see citing works

Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217 · see citing works

Durable Clinical Benefit with Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer

Overman, M. J., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.9901 · Cited by 2,079 · see citing works

Immunotherapy in colorectal cancer: Rationale, challenges and potential

Ganesh, K., Stadler, Z. K., Cercek, A., Mendelsohn, R. B., Shia, J., Segal, N. H., & Diaz, L. A. (2019) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-019-0126-x · Cited by 1,954 · see citing works

Regulation of short-chain fatty acid production

Macfarlane, S., & Macfarlane, G. T. (2003) · Proceedings of the Nutrition Society · doi:10.1079/pns2002207 · Cited by 1,939 · see citing works

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917 · see citing works

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity

Vanpouille-Box, C., Alard, A., Aryankalayil, M. J., Sarfraz, Y., Diamond, J. M., Schneider, R. J., Inghirami, G., Coleman, C. N., Formenti, S. C., & Demaria, S. (2017) · Nature Communications · doi:10.1038/ncomms15618 · Cited by 1,834 · see citing works

L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity

Geiger, R., Rieckmann, J. C., Wolf, T., Basso, C., Feng, Y., Fuhrer, T., Kogadeeva, M., Picotti, P., Meissner, F., Mann, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.09.031 · Cited by 1,775 · see citing works

High burden and pervasive positive selection of somatic mutations in normal human skin

Martincorena, I., Roshan, A., Gerstung, M., Ellis, P., Van Loo, P., McLaren, S., Wedge, D. C., Fullam, A., Alexandrov, L. B., Tubio, J. M., et al. (2015) · Science · doi:10.1126/science.aaa6806 · Cited by 1,770 · see citing works

Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial

Bahadoer, R. R., Dijkstra, E. A., van Etten, B., Marijnen, C. A. M., Putter, H., Kranenbarg, E. M., Roodvoets, A. G. H., Nagtegaal, I. D., Beets‐Tan, R. G. H., Blomqvist, L. K., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30555-6 · Cited by 1,706 · see citing works

PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer

Cercek, A., Lumish, M. A., Sinopoli, J. C., Weiss, J. A., Shia, J., Lamendola-Essel, M. F., Dika, I. H. E., Segal, N. H., Shcherba, M., Sugarman, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2201445 · Cited by 1,665 · see citing works

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527 · see citing works

Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics

Cronin, K. A., Lake, A. J., Scott, S., Sherman, R., Noone, A., Howlader, N., Henley, S. J., Anderson, R. N., Firth, A. U., Ma, J., et al. (2018) · Cancer · doi:10.1002/cncr.31551 · Cited by 1,486 · see citing works

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

Chalabi, M., Fanchi, L. F., Dijkstra, K. K., Van den Berg, J. G., Aalbers, A. G., Sikorska, K., Lopez-Yurda, M., Grootscholten, C., Beets, G. L., Snaebjornsson, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0805-8 · Cited by 1,417 · see citing works

Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy

Mager, L. F., Burkhard, R., Pett, N., Cooke, N. C. A., Brown, K., Ramay, H., Paik, S., Stagg, J., Groves, R. A., Gallo, M., et al. (2020) · Science · doi:10.1126/science.abc3421 · Cited by 1,407 · see citing works

T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer

Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368 · see citing works

Human dendritic cell subsets: an update

Collin, M., & Bigley, V. (2018) · Immunology · doi:10.1111/imm.12888 · Cited by 1,301 · cited 2× · see citing works

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

Robbins, P. F., Lu, Y., El‐Gamil, M., Li, Y. F., Gross, C. A., Gartner, J. J., Lin, J., Teer, J. K., Cliften, P. F., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,074 · see citing works

Sodium butyrate inhibits histone deacetylation in cultured cells

Candido, E. (1978) · Cell · doi:10.1016/0092-8674(78)90305-7 · Cited by 1,036 · see citing works

Classification and characterization of microsatellite instability across 18 cancer types

Hause, R. J., Pritchard, C. C., Shendure, J., & Salipante, S. J. (2016) · Nature Medicine · doi:10.1038/nm.4191 · Cited by 982 · see citing works

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin‐Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.075 · Cited by 912 · see citing works

Tumour-targeting bacteria engineered to fight cancer

Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821 · see citing works

Epigenetics of colorectal cancer: biomarker and therapeutic potential

Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-019-0230-y · Cited by 813 · see citing works

Natural killer cells in antitumour adoptive cell immunotherapy

Laskowski, T. J., Biederstädt, A., & Rezvani, K. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00491-0 · Cited by 784 · see citing works

Genetic instability and darwinian selection in tumours

Cahill, D. P., Kinzler, K. W., Vogelstein, B., & Christoph Lengauer, C. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01661-x · Cited by 747 · see citing works

Epigenetics and colorectal cancer

Lao, V. V., & Grady, W. M. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.173 · Cited by 734 · see citing works

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study

Lenz, H.-J., Van Cutsem, E., Luisa Limon, M., Wong, K. Y. M., Hendlisz, A., Aglietta, M., García-Alfonso, P., Neyns, B., Luppi, G., Cardin, D. B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01015 · Cited by 728 · see citing works

Radiotherapy combined with immunotherapy: the dawn of cancer treatment

Zhang, Z., Liu, X., Chen, D., & Yu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01102-y · Cited by 695 · see citing works

Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy

Wang, J., Sun, J., Liu, L. N., Flies, D. B., Nie, X., Toki, M. I., Zhang, J., Song, C. C., Zarr, M. A., Zhou, X., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0374-x · Cited by 676 · see citing works

Impact of oncogenic pathways on evasion of antitumour immune responses

Spranger, S., & Gajewski, T. F. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.117 · Cited by 663 · see citing works

TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy

Molgora, M., Esaulova, E., Vermi, W., Hou, J., Chen, Y., Luo, J., Brioschi, S., Bugatti, M., Omodei, A. S., Ricci, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.013 · Cited by 656 · cited 1× · see citing works

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer

Schrock, A. B., Ouyang, C., Sandhu, J. S., Sokol, E. S., Jin, D. X., Ross, J. S., Miller, V. A., Lim, D. W., Amanam, I. U., Chao, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz134 · Cited by 620 · see citing works

Metabolic modulation of tumours with engineered bacteria for immunotherapy

Canale, F. P., Basso, C., Antonini, G., Perotti, M., Li, N., Sokolovska, A., Neumann, J., James, M. J., Geiger, S., Jin, W., et al. (2021) · Nature · doi:10.1038/s41586-021-04003-2 · Cited by 619 · see citing works

KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer

Liao, W., Overman, M. J., Boutin, A. T., Shang, X., Zhao, D., Dey, P., Li, J., Wang, G., Lan, Z., Li, J., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.008 · Cited by 617 · cited 1× · see citing works

Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors

Grosser, R., Cherkassky, L., Chintala, N., & Adusumilli, P. S. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.006 · Cited by 603 · see citing works

Drug resistance and new therapies in colorectal cancer

Jeught, K. V. D., Xu, H.-C., Li, Y.-J., Lu, X.-B., & Ji, G. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i34.3834 · Cited by 597 · see citing works

Immune and stromal classification of colorectal cancer is associated with molecular subtypes and relevant for precision immunotherapy

Becht, E., de Reyniès, A., Giraldo, N. A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., & Fridman, W. H. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2879 · Cited by 590 · see citing works

Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

Wellenstein, M. D., & de Visser, K. E. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.004 · Cited by 581 · see citing works

Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis

Xu, C., Chen, Y., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G., Li, W., Mao, Y., Hsu, C., et al. (2018) · BMJ · doi:10.1136/bmj.k4226 · Cited by 560 · see citing works

Identification of neoantigens for individualized therapeutic cancer vaccines

Lang, F., Schrörs, B., Löwer, M., Türeci, Ö., & Şahin, U. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00387-y · Cited by 553 · see citing works

Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

Lipson, E. J., Sharfman, W. H., Drake, C. G., WOLLNER, I. S., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 546 · see citing works

Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy

Fong, L. H., Hou, Y., Rivas, A., Benike, C. J., Yuen, A. R., Fisher, G. A., Davis, M. M., & Engleman, E. G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141226398 · Cited by 540 · see citing works

Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer

Picard, E., Verschoor, C. P., Grace, W. K., & Pawelec, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00369 · Cited by 520 · see citing works

An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors

Reinhard, K., Rengstl, B., Oehm, P., Michel, K., Billmeier, A., Hayduk, N., Klein, O., Kuna, K., Ouchan, Y., Wöll, S., et al. (2020) · Science · doi:10.1126/science.aay5967 · Cited by 512 · see citing works

Radiotherapy combination opportunities leveraging immunity for the next oncology practice

Herrera, F. G., Bourhis, J., & Coukos, G. (2016) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21358 · Cited by 511 · see citing works

Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth

Zagato, E., Pozzi, C., Bertocchi, A., Schioppa, T., Saccheri, F., Guglietta, S., Fosso, B., Melocchi, L., Nizzoli, G., Troisi, J., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-019-0649-5 · Cited by 506 · see citing works

Immune-related adverse events of immune checkpoint inhibitors: a review

Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., & Bian, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1167975 · Cited by 466 · see citing works

Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity

Leventhal, D. S., Sokolovska, A., Li, N., Plescia, C., Kolodziej, S. A., Gallant, C. W., Christmas, R., Gao, J.-R., James, M. J., Abin-Fuentes, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16602-0 · Cited by 458 · see citing works

Targeting of cancer neoantigens with donor-derived T cell receptor repertoires

Strønen, E., Toebes, M., Kelderman, S., van Buuren, M. M., Yang, W., van Rooij, N., Donia, M., Böschen, M.-L., Lund‐Johansen, F., Olweus, J., et al. (2016) · Science · doi:10.1126/science.aaf2288 · Cited by 444 · see citing works

mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

Cafri, G., Gartner, J. J., Zaks, T., Hopson, K., Levin, N., Paria, B. C., Parkhurst, M. R., Yossef, R., Lowery, F. J., Jafferji, M. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134915 · Cited by 427 · see citing works

Intratumoral accumulation of gut microbiota facilitates CD47-based immunotherapy via STING signaling

Shi, Y., Zheng, W., Yang, K., Harris, K. G., Ni, K., Xue, L., Lin, W., Chang, E. B., Weichselbaum, R. R., & Fu, Y. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192282 · Cited by 409 · see citing works

Immune modulatory effects of oncogenic KRAS in cancer

Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020) · Nature Communications · doi:10.1038/s41467-020-19288-6 · Cited by 387 · see citing works

Targeting a neoantigen derived from a common <i>TP53</i> mutation

Hsiue, E. H.-C., Wright, K. M., Douglass, J., Hwang, M. S., Mog, B. J., Pearlman, A. H., Paul, S., DiNapoli, S. R., Konig, M. F., Wang, Q., et al. (2021) · Science · doi:10.1126/science.abc8697 · Cited by 367 · see citing works

Mutant p53 Suppresses Innate Immune Signaling to Promote Tumorigenesis

Ghosh, M., Saha, S., Bettke, J. A., Nagar, R., Parrales, A., Iwakuma, T., van der Velden, A. W. M., & Martinez, L. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2021.01.003 · Cited by 344 · see citing works

Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction

Wang, T., Gnanaprakasam, J. R., Chen, X., Kang, S., Xu, X., Sun, H., Liu, L., Rodgers, H., Miller, E., Cassel, T., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0219-4 · Cited by 333 · see citing works

Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients

Xiao, L., Cen, D., Gan, H., Sun, Y., Huang, N., Xiong, H., Jin, Q., Su, L., Liu, X., Wang, K., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.03.011 · Cited by 329 · see citing works

Mutational Analysis of Patients with Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome

Innocenti, F., Ou, F.-S., Qu, X., Zemla, T. J., Niedzwiecki, D., Tam, R., Mahajan, S., Goldberg, R. M., Bertagnolli, M. M., Blanke, C. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01798 · Cited by 317 · see citing works

Phase II Study of the Anti-Cytotoxic T-Lymphocyte–Associated Antigen 4 Monoclonal Antibody, Tremelimumab, in Patients With Refractory Metastatic Colorectal Cancer

Chung, K. Y., Gore, I., Fong, L. H., Venook, A. P., Beck, S. B., Dorazio, P., Criscitiello, P. J., Healey, D. I., Huang, B., Gómez-Navarro, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.3994 · Cited by 307 · see citing works

Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy

Goodman, A. M., Sokol, E. S., Frampton, G. M., Lippman, S. M., & Kurzrock, R. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0149 · Cited by 306 · see citing works

A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen.

Morse, M. A., Deng, Y., Coleman, D., Hull, S., Kitrell-Fisher, E., Nair, S. K., Schlom, J., Ryback, M. E., & Lyerly, H. K. (1999) · PubMed · Cited by 300 · see citing works

Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial

Parikh, A. R., Szabolcs, A., Allen, J. N., Clark, J. W., Wo, J. Y.-L., Raabe, M. J., Thel, H. L., Hoyos, D., Mehta, A., Arshad, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00269-7 · Cited by 298 · see citing works

A randomized double-blind placebo-controlled trial of probiotics in post-surgical colorectal cancer

Zaharuddin, L., Mokhtar, N. M., Nawawi, K. N. M., & Ali, R. A. R. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-1047-4 · Cited by 292 · see citing works

DNA Sensing in Mismatch Repair-Deficient Tumor Cells Is Essential for Anti-tumor Immunity

Lu, C., Guan, J., Lu, S., Jin, Q., Rousseau, B., Lu, T., Stephens, D., Zhang, H., Zhu, J., Yang, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.006 · Cited by 285 · see citing works

Mechanisms driving the immunoregulatory function of cancer cells

van Weverwijk, A., & de Visser, K. E. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-022-00544-4 · Cited by 279 · see citing works

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

André, T., Lonardi, S., Wong, K. Y. M., Lenz, H.-J., Gelsomino, F., Aglietta, M., Morse, M. A., Van Cutsem, E., McDermott, R., Hill, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.06.008 · Cited by 270 · see citing works

Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial.

Hoover, H. C., Brandhorst, J. S., Peters, L. C., Surdyke, M. G., Takeshita, Y., Madariaga, J., Muenz, L. R., & Hanna, M. G. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.390 · Cited by 259 · see citing works

Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma

Giannakis, M., Mu, X. J., Shukla, S. A., Qian, Z. R., Cohen, O., Nishihara, R., Bahl, S., Cao, Y., Amin‐Mansour, A., Yamauchi, M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.009 · Cited by 259 · see citing works

Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy

Maby, P., Tougeron, D., Hamieh, M., Mlecnik, B., Kora, H., Bindea, G., Angell, H. K., Fredriksen, T., Elie, N., Fauquembergue, É., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3051 · Cited by 250 · see citing works

The association between tumor mutational burden and prognosis is dependent on treatment context

Valero, C., Lee, M. A., Hoen, D. R., Wang, J., Nadeem, Z., Patel, N., Postow, M. A., Shoushtari, A. N., Plitas, G., Balachandran, V. P., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00752-4 · Cited by 249 · see citing works

The Immune Biology of Microsatellite-Unstable Cancer

Kloor, M., & Doeberitz, M. V. K. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.02.004 · Cited by 242 · see citing works

The Contribution of Epigenetics to Cancer Immunotherapy

Villanueva, L., Álvarez‐Errico, D., & Esteller, M. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.002 · Cited by 234 · see citing works

Pectin supplement significantly enhanced the anti-PD-1 efficacy in tumor-bearing mice humanized with gut microbiota from patients with colorectal cancer

Zhang, S., Mao, Y., Zhang, Z.-Y., Li, Z., Kong, C., Chen, H., Cai, P., Han, B., Ye, T., & Wang, L. (2021) · Theranostics · doi:10.7150/thno.54476 · Cited by 232 · see citing works

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study

Qian, D. C., Kleber, T., Brammer, B., Xu, K. M., Switchenko, J. M., Janopaul-Naylor, J. R., Zhong, J., Yushak, M. L., Harvey, R. D., Paulos, C. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00546-5 · Cited by 223 · see citing works

Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer

Zhang, H., Pandey, S., Travers, M. E., Sun, H., Morton, G. C., Madžo, J., Chung, W., Khowsathit, J., Pérez, Ó. C., Barrero, C. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.051 · Cited by 218 · see citing works

WNT Signaling in Tumors: The Way to Evade Drugs and Immunity

Martín-Orozco, E., Sánchez-Fernández, A., Ortiz-Parra, I., & Nicolas, M. A.-S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02854 · Cited by 218 · see citing works

Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

McMeekin, D. S., Tritchler, D., Cohn, D. E., Mutch, D. G., Lankes, H. A., Geller, M. A., Powell, M. A., Backes, F. J., Landrum, L. M., Zaino, R. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.8722 · Cited by 210 · see citing works

Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance

Park, J. S., Gazzaniga, F. S., Wu, M., Luthens, A. K., Gillis, J., Zheng, W., LaFleur, M. W., Johnson, S. B., Morad, G., Park, E. M., et al. (2023) · Nature · doi:10.1038/s41586-023-06026-3 · Cited by 191 · see citing works

LBA7 Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study

Chalabi, M., Verschoor, Y. L., van den Berg, J. G., Sikorska, K., Beets, G. L., van Lent, A. U., Grootscholten, M. C., Aalbers, A., Buller, N., Marsman, H. A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.016 · Cited by 191 · see citing works

Defining and Understanding Adaptive Resistance in Cancer Immunotherapy

Kim, T. K., Herbst, R. S., & Chen, L. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.05.001 · Cited by 189 · see citing works

mRNA-based dendritic cell vaccines

Benteyn, D., Heirman, C., Bonehill, A., Thielemans, K., & Breckpot, K. (2014) · Expert Review of Vaccines · doi:10.1586/14760584.2014.957684 · Cited by 181 · see citing works

Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer

Westcott, P. M. K., Sacks, N. J., Schenkel, J. M., Ely, Z. A., Smith, O. C. G., Hauck, H., Jaeger, A. M., Zhang, D., Backlund, C. M., Beytagh, M. C., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00247-z · Cited by 180 · see citing works

Immunotherapy with Autologous, Human Dendritic Cells Transfected with Carcinoembryonic Antigen mRNA: ORIGINAL ARTICLE

Morse, M. A., Nair, S. K., Mosca, P. J., Hobeika, A. C., Clay, T. M., Deng, Y., Boczkowski, D., Proia, A., Neidzwiecki, D., Clavien#, P.-A., et al. (2003) · Cancer Investigation · doi:10.1081/cnv-120018224 · Cited by 177 · see citing works

Gut Microbiome Influences the Efficacy of PD-1 Antibody Immunotherapy on MSS-Type Colorectal Cancer via Metabolic Pathway

Xu, X., Lv, J., Guo, F., Li, J., Jia, Y., Jiang, D., Wang, N., Zhang, C., Kong, L., Liu, Y., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00814 · Cited by 173 · see citing works

Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity

Westcott, P. M. K., Muyas, F., Hauck, H., Smith, O. C. G., Sacks, N. J., Ely, Z. A., Jaeger, A. M., Rideout, W. M., Zhang, D., Bhutkar, A. J., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01499-4 · Cited by 170 · see citing works

Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity

Guo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168 · see citing works

Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Induces Immune Responses which Correlate with Disease Control: A Phase I/II Trial

Harrop, R., Connolly, N. B., Redchenko, I., Valle, J. W., Saunders, M. P., Ryan, M. G., Myers, K. A., Drury, N. L., Kingsman, S. M., Hawkins, R. E., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2732 · Cited by 166 · see citing works

Immunologic Recognition of a Shared p53 Mutated Neoantigen in a Patient with Metastatic Colorectal Cancer

Lo, W. M., Parkhurst, M. R., Robbins, P. F., Tran, E., Lu, Y., Jia, L., Gartner, J. J., Pasetto, A., Deniger, D. C., Malekzadeh, P., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0686 · Cited by 156 · see citing works

Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors

Shao, C., Li, G., Huang, L., Pruitt, S. K., Castellanos, E. H., Frampton, G. M., Carson, K. R., Snow, T., Singal, G., Fabrizio, D. A., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.25109 · Cited by 155 · see citing works

Current approaches in dendritic cell generation and future implications for cancer immunotherapy

Tuyaerts, S., Aerts, J. L., Corthals, J., Neyns, B., Heirman, C., Breckpot, K., Thielemans, K., & Bonehill, A. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0334-z · Cited by 155 · see citing works

Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer

Opzoomer, J. W., Sosnowska, D., Anstee, J. E., Spicer, J. F., & Arnold, J. N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01654 · Cited by 150 · see citing works

Challenges in neoantigen-directed therapeutics

Lybaert, L., Lefever, S., Fant, B., Smits, E., Geest, B. G. D., Breckpot, K., Dirix, L. Y., Feldman, S. A., Criekinge, W. V., Thielemans, K., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.013 · Cited by 146 · see citing works

Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens

Wagner, S., Mullins, C. S., & Linnebacher, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i48.5418 · Cited by 144 · see citing works

Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies

Taı̈eb, J., Shi, Q., Pederson, L., Alberts, S. R., Wolmark, N., Cutsem, E. V., de Gramont, A., Kerr, R. S., Grothey, A. F., Lonardi, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz208 · Cited by 135 · see citing works

Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN–driven CCL5 and CXCL10

Mowat, C., Mosley, S. R., Namdar, A., Schiller, D., & Baker, K. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210108 · Cited by 134 · see citing works

Increased stiffness of the tumor microenvironment in colon cancer stimulates cancer associated fibroblast-mediated prometastatic activin A signaling

Bauer, J., Emon, M. A. B., Staudacher, J. J., Thomas, A. L., Zessner-Spitzenberg, J., Mancinelli, G., Krett, N., Saif, M. T., & Jung, B. (2020) · Scientific Reports · doi:10.1038/s41598-019-55687-6 · Cited by 133 · see citing works

Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape

Takeuchi, Y., Tanegashima, T., Sato, E., Irie, T., Sai, A., Itahashi, K., Kumagai, S., Tada, Y., Togashi, Y., Koyama, S., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abc6424 · Cited by 132 · see citing works

LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy

Sharma, N., Atolagbe, O. T., Ge, Z., & Allison, J. P. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201811 · Cited by 131 · see citing works

PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis

Hecht, M., Büttner-Herold, M. J., Erlenbach‐Wünsch, K., Haderlein, M., Croner, R. S., Grützmann, R., Hartmann, A., Fietkau, R., & Distel, L. V. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.015 · Cited by 127 · see citing works

Microbial ecosystems therapeutics: a new paradigm in medicine?

Petrof, E., Claud, E. C., Gloor, G. B., & Allen‐Vercoe, E. (2012) · Beneficial Microbes · doi:10.3920/bm2012.0039 · Cited by 124 · see citing works

Improving CAR T-Cell Persistence

Pietrobon, V., Todd, L. A., Goswami, A., Stefanson, O., Yang, Z., & Marincola, F. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910828 · Cited by 118 · see citing works

Safety of nivolumab plus low-dose ipilimumab in previously treated microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer

Morse, M. A., Overman, M. J., Hartman, L., Khoukaz, T., Brutcher, E., Lenz, H.-J., Atasoy, A., Shangguan, T., Zhao, H., & El-Rayes, B. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0129 · Cited by 112 · see citing works

A Randomized Trial ofEx vivoCD40L Activation of a Dendritic Cell Vaccine in Colorectal Cancer Patients: Tumor-Specific Immune Responses Are Associated with Improved Survival

Barth, R. J., Fisher, D. A., Wallace, P. K., Channon, J. Y., Noelle, R. J., Gui, J., & Ernstoff, M. S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2138 · Cited by 109 · see citing works

An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity

Zhou, Z., Van der Jeught, K., Fang, Y., Yu, T., Li, Y., Ao, Z., Liu, S., Zhang, L., Yang, Y., Eyvani, H., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00805-x · Cited by 107 · see citing works

Mechanisms of Tumor Cell–Intrinsic Immune Evasion

Spranger, S., & Gajewski, T. F. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050606 · Cited by 107 · see citing works

Neo-Antigen mRNA Vaccines

Esprit, A., de Mey, W., Shahi, R. B., Thielemans, K., Franceschini, L., & Breckpot, K. (2020) · Vaccines · doi:10.3390/vaccines8040776 · Cited by 105 · see citing works

Phase i trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma

Bilusic, M., Heery, C. R., Arlen, P. M., Rauckhorst, M., Apelian, D., Tsang, K. Y., Tucker, J. A., Jochems, C., Schlom, J., Gulley, J. L., et al. (2014) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-013-1505-8 · Cited by 102 · see citing works

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer

Chua, W., Goldstein, D., Lee, C. K., Dhillon, H. M., Michael, M., Mitchell, P., Clarke, S. J., & Iacopetta, B. M. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605239 · Cited by 101 · see citing works

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response

Temko, D., van Gool, I. C., Rayner, E., Glaire, M. A., Makino, S., Brown, M., Chegwidden, L., Palles, C., Depreeuw, J., Beggs, A. D., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5081 · Cited by 100 · see citing works

Degree and site of chromosomal instability define its oncogenic potential

Hoevenaar, W. H. M., Janssen, A., Quirindongo, A. I., Ma, H., Klaasen, S. J., Teixeira, A., van Gerwen, B., Lansu, N. R., Morsink, F. H. M., Offerhaus, G. J. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15279-9 · Cited by 100 · see citing works

Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response

Roelands, J. P., Hendrickx, W., Zoppoli, G. M., Mall, R., Saad, M., Halliwill, K. D., Curigliano, G., Rinchai, D., Decock, J. V., Delogu, L. G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000617 · Cited by 99 · see citing works

Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.

Lesterhuis, W. J., de Vries, I. J. M., Schreibelt, G., Schuurhuis, D. H., Aarntzen, E. H. J. G., de Boer, A. J., Scharenborg, N. M., van de Rakt, M. W. M. M., Hesselink, E. J., Figdor, C. G., et al. (2010) · PubMed · Cited by 97 · see citing works

Tumor Microenvironment Shapes Colorectal Cancer Progression, Metastasis, and Treatment Responses

Li, J., Chen, D., & Shen, M. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.869010 · Cited by 94 · see citing works

Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.

Schwitalle, Y., Linnebacher, M., Ripberger, E., Gebert, J. F., & Doeberitz, M. V. K. (2004) · PubMed · Cited by 93 · see citing works

Preclinical Evaluation of Chimeric Antigen Receptor–Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer

Zhang, B.-L., Li, D., Gong, Y.-L., Huang, Y., Qin, D.-Y., Jiang, L., Liang, X., Yang, X., Gou, H.-F., Wang, Y.-S., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.229 · Cited by 88 · see citing works

A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours

Kang, Y., O’Haire, S., Franchini, F., IJzerman, M. J., Zalcberg, J. R., Macrae, F., Canfell, K., & Steinberg, J. (2022) · Scientific Reports · doi:10.1038/s41598-022-23319-1 · Cited by 88 · see citing works

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study

Azad, N. S., El-Khoueiry, A. B., Yin, J., Oberg, A. L., Flynn, P. J., Adkins, D., Sharma, A. R., Weisenberger, D. J., Brown, T. D., Medvari, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15108 · Cited by 88 · see citing works

A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

Hazama, S., Nakamura, Y., Tanaka, H., Hirakawa, K., TAHARA, K., Shimizu, R., Ozasa, H., Etoh, R., Sugiura, F., Okuno, K., et al. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-108 · Cited by 87 · see citing works

Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells

Aparicio, C., Belver, M., Enríquez, L., Espeso, F., Núñez, L., Sánchez, A., de la Fuente, M. Á., & González‐Vallinas, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111781 · Cited by 86 · see citing works

Lynch Syndrome and MSI-H Cancers: From Mechanisms to “Off-The-Shelf” Cancer Vaccines

Roudko, V., Bozkus, C. C., Greenbaum, B. D., Lucas, A. L., Samstein, R. M., & Bhardwaj, N. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.757804 · Cited by 86 · see citing works

Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer

Segal, N. H., Cercek, A., Ku, G. Y., Wu, A. J.-C., Rimner, A., Khalil, D. N., Reidy‐Lagunes, D. L., Cuaron, J. J., Yang, J. T., Weiser, M. R., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2474 · Cited by 85 · see citing works

Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer

Huang, J., Xing, Z., Kang, W., Hao, H., Mao, Y., Zhang, H., Chen, Y., Tan, Y. Q., He, Y., Zhao, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.874922 · Cited by 81 · see citing works

A Metabolism Toolbox for CAR T Therapy

Xu, X., Gnanaprakasam, J. R., Sherman, J. W., & Wang, R. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00322 · Cited by 81 · see citing works

Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen

Itoh, T., Ueda, Y., Kawashima, I., Nukaya, I., Fujiwara, H., Fuji, N., Yamashita, T., Yoshimura, T., Okugawa, K., Iwasaki, T., et al. (2002) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-001-0257-z · Cited by 80 · see citing works

Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications

Moretto, R., Elliott, A., Zhang, J., Arai, H., Germani, M. M., Conca, V., Xiu, J., Stafford, P., Oberley, M. J., Abraham, J. P., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab169 · Cited by 77 · see citing works

Genetic instability and darwinian selection in tumours

Cahill, D. P., Kinzler, K. W., Vogelstein, B., & Christoph Lengauer, C. (1999) · Trends in Genetics · doi:10.1016/s0168-9525(99)01874-0 · Cited by 77 · see citing works

Cancer vaccines: past, present and future; a review article

Grimmett, E., Al-Share, B. A., Alkassab, M. B., Zhou, R. W., Desai, A., Rahim, M. M. A., & Woldie, I. (2022) · Discover Oncology · doi:10.1007/s12672-022-00491-4 · Cited by 72 · see citing works

Targeting the tumor microenvironment to enhance antitumor immune responses

der Jeught, K. V., Bialkowski, L., Daszkiewicz, L., Broos, K., Goyvaerts, C., Renmans, D., Lint, S. V., Heirman, C., Thielemans, K., & Breckpot, K. (2014) · Oncotarget · doi:10.18632/oncotarget.3204 · Cited by 68 · see citing works

Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells

Breckpot, K., Heirman, C., Neyns, B., & Thielemans, K. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.615 · Cited by 68 · see citing works

Clinical Benefit of Allogeneic Melanoma Cell Lysate–Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients

Toh, H. C., Wang, W.-W., Chia, W. K., Kvistborg, P., Sun, L. J., Teo, K., Phoon, Y. P., Soe, Y., Tan, S. H., Hee, S. W., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1537 · Cited by 66 · see citing works

Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors

Murahashi, M., Hijikata, Y., Yamada, K., Tanaka, Y., Kishimoto, J., Inoue, H., Marumoto, T., Takahashi, A., Okazaki, T., Takeda, K., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.03.015 · Cited by 66 · see citing works

A T Cell‐Engaging Tumor Organoid Platform for Pancreatic Cancer Immunotherapy

Zhou, Z., der Jeught, K. V., Li, Y., Sharma, S., Yu, T., Moulana, I., Liu, S., Wan, J., Territo, P. R., Opyrchal, M., et al. (2023) · Advanced Science · doi:10.1002/advs.202300548 · Cited by 65 · see citing works

HSP110 T17 simplifies and improves the microsatellite instability testing in patients with colorectal cancer

Buhard, O., Lagrange, A., Guilloux, A., Colas, C., Chouchène, M., Wanherdrick, K., Coulet, F., Guillerm, E., Dorard, C., Marisa, L., et al. (2016) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2015-103518 · Cited by 63 · see citing works

Colorectal cancer vaccines: The current scenario and future prospects

Jia, W., Zhang, T., Huang, H., Feng, H., Wang, S., Guo, Z., Luo, Z., Ji, X., Cheng, X., & Zhao, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.942235 · Cited by 62 · see citing works

Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers

Lhuillier, C., Vanpouille‐Box, C., Galluzzi, L., Formenti, S. C., & Demaria, S. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.007 · Cited by 62 · see citing works

Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients

Snook, A. E., Baybutt, T. R., Xiang, B., Abraham, T. S., Flickinger, J. C., Hyslop, T., Zhan, T., Kraft, W. K., Sato, T., & Waldman, S. A. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0576-2 · Cited by 62 · see citing works

Genomic Instability and Cancer Risk Associated with Erroneous DNA Repair

Yoshioka, K., Kusumoto‐Matsuo, R., Matsuno, Y., & Ishiai, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212254 · Cited by 60 · see citing works

Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients

Alfaro, C., Perez‐Gracia, J. L., Suárez, N., Rodríguez, J., Sanmamed, M. F., Sangro, B., Martín‐Algarra, S., Calvo, A., Redrado, M., Agliano, A., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102209 · Cited by 60 · see citing works

The antigen‐binding moiety in the driver's seat of CARs

Hanssens, H., Meeus, F., Veirman, K. D., Breckpot, K., & Devoogdt, N. (2021) · Medicinal Research Reviews · doi:10.1002/med.21818 · Cited by 60 · see citing works

Cancer neoantigens as potential targets for immunotherapy

Ma, W., Pham, B., & Li, T. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10091-1 · Cited by 58 · see citing works

Role of the cGAS-STING pathway in regulating the tumor-immune microenvironment in dMMR/MSI colorectal cancer

Kaneta, A., Nakajima, S., Okayama, H., Matsumoto, T., Saito, K., Kikuchi, T., Endo, E., Ito, M., Mimura, K., Kanke, Y., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03200-w · Cited by 58 · see citing works

Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients

Caballero‐Baños, M., Benítez‐Ribas, D., Tabera, J., Varea, S., Vilana, R., Bianchi, L., Ayuso, J. R., Pagés, M., Carrera, G., Cuatrecasas, M., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.008 · Cited by 57 · see citing works

A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis

Rodríguez, J., Álvarez, E. C., Perez‐Gracia, J. L., Rodríguez, I., Viúdez, A., Alfaro, C., Oñate, C., Pérez, G., Rotellar, F., Inogés, S., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0405-z · Cited by 57 · see citing works

Evolving neoantigen profiles in colorectal cancers with DNA repair defects

Rospo, G., Lorenzato, A., Amirouchene-Angelozzi, N., Magrì, A., Cancelliere, C., Corti, G., Negrino, C., Amodio, V., Montone, M., Bartolini, A., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0654-6 · Cited by 56 · see citing works

The old CEACAMs find their new role in tumor immunotherapy

Han, Z.-W., Lyv, Z.-W., Cui, B., Wang, Y., Cheng, J.-T., Zhang, Y., Cai, W.-Q., Zhou, Y., Ma, Z., Wang, X.-W., et al. (2020) · Investigational New Drugs · doi:10.1007/s10637-020-00955-w · Cited by 49 · see citing works

Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types

Sinha, N., Sinha, S., Valero, C., Schäffer, A. A., Aldape, K., Litchfield, K., Chan, T. A., Morris, L. G. T., & Ruppin, E. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2542 · Cited by 49 · see citing works

Dendritic cell vaccine therapy for colorectal cancer

McCormick, A. L., Girgis, L. H., Brazeale, H. S., Anderson, T. S., Wood, L. M., & Lowe, D. B. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105374 · Cited by 48 · see citing works

ST2 as checkpoint target for colorectal cancer immunotherapy

der Jeught, K. V., Sun, Y., Fang, Y., Zhou, Z., Jiang, H., Yu, T., Yang, J., Kamocka, M. M., So, K. M., Li, Y., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.136073 · Cited by 48 · see citing works

Immune Checkpoint Inhibition in Metastatic Colorectal Cancer Harboring Microsatellite Instability or Mismatch Repair Deficiency

Cohen, R., Colle, R., Pudlarz, T., Heran, M., Duval, A., Svrcek, M., & André, T. (2021) · Cancers · doi:10.3390/cancers13051149 · Cited by 47 · see citing works

Tumor CEMIP drives immune evasion of colorectal cancer via MHC-I internalization and degradation

Zhang, B., Li, J., Hua, Q., Wang, H., Xu, G., Chen, J., Zhu, Y., Li, R., Liang, Q. D., Wang, L., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005592 · Cited by 46 · see citing works

The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer

Arai, H., Elliott, A., Xiu, J., Wang, J., Battaglin, F., Kawanishi, N. K., Soni, S., Zhang, W., Millstein, J., Sohal, D. P. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3635 · Cited by 43 · see citing works

Whole recombinant Saccharomyces cerevisiae yeast expressing Ras mutations as treatment for patients with solid tumors bearing Ras mutations: Results from a phase 1 trial

Cohn, A., Morse, M. A., O’Neil, B., Whiting, S., Coeshott, C., Ferraro, J., Bellgrau, D., Apelian, D., & Rodell, T. C. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000219 · Cited by 41 · see citing works

Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer

Yu, Y., Shan, N., Li, L., Zhu, Y., Lin, L., Mao, C., Hu, T., Xue, X., Su, X., Shen, X., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03386-7 · Cited by 40 · see citing works

Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer

Yu, Y., Zhang, J., Ni, L., Zhu, Y., Yu, H., Teng, Y., Lin, L., Xue, Z., Xue, X., Shen, X., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1891814 · Cited by 39 · see citing works

Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer

Manz, S., Losa, M., Fritsch, R., & Scharl, M. M. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211002018 · Cited by 33 · see citing works

The DNA damage induced immune response: Implications for cancer therapy

Barros, E. M., McIntosh, S., & Savage, K. I. (2022) · DNA repair · doi:10.1016/j.dnarep.2022.103409 · Cited by 33 · see citing works

Disruption of β-Catenin–Dependent Wnt Signaling in Colon Cancer Cells Remodels the Microenvironment to Promote Tumor Invasion

Chen, G. T., Tifrea, D. F., Murad, R., Habowski, A. N., Lyou, Y., Duong, M. R., Hosohama, L., Mortazavi, A., Edwards, R. A., & Waterman, M. L. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0349 · Cited by 30 · see citing works

Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review

Juat, D. J., Hachey, S. J., Billimek, J., Rosario, M. P. D., Nelson, E. L., Hughes, C. C. W., & Zell, J. A. (2022) · The Oncologist · doi:10.1093/oncolo/oyab038 · Cited by 27 · see citing works

CLEC-1 is a death sensor that limits antigen cross-presentation by dendritic cells and represents a target for cancer immunotherapy

Drouin, M., Coronilla, J. S., Gauttier, V., Berangere, E., Teppaz, G., Pengam, S., Mary, C., Desselle, A., Thépenier, V., Wilhelm, E., et al. (2022) · Science Advances · doi:10.1126/sciadv.abo7621 · Cited by 26 · see citing works

RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System

de Mey, W., Esprit, A., Thielemans, K., Breckpot, K., & Franceschini, L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3304 · Cited by 25 · see citing works

Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation—A Special Reference to Colorectal Cancer

Koulouridi, A., Messaritakis, I., Gouvas, N., Tsiaoussis, J., & Souglakos, J. (2020) · Cancers · doi:10.3390/cancers13010043 · Cited by 24 · see citing works

T cells of colorectal cancer patients’ stimulated by neoantigenic and cryptic peptides better recognize autologous tumor cells

Schwarz, S., Schmitz, J., Loeffler, M. W., Ghosh, M., Rammensee, H., Olshvang, E., Markel, M., Mockel-Tenbrinck, N., Dzionek, A., Krake, S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005651 · Cited by 24 · see citing works

Autologous Dendritic Cell Based Adoptive Immunotherapy of Patients with Colorectal Cancer—A Phase I-II Study

Hunyadi, J., András, C., Szabó, I., Szántó, J., Szluha, K., Sipka, S., Kovacs, P. L., Kiss, A., Szegedi, G., Altorjay, I., et al. (2013) · Pathology & Oncology Research · doi:10.1007/s12253-013-9704-3 · Cited by 23 · see citing works

Microbial metabolite boosts immunotherapy

Bird, L. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-00465-z · Cited by 22 · see citing works

Ex vivo dendritic cell generation—A critical comparison of current approaches

Han, P., Hanlon, D. J., Sobolev, O., Chaudhury, R., & Edelson, R. L. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.10.003 · Cited by 22 · see citing works

Tumor RNA transfected DCs derived from iPS cells elicit cytotoxicity against cancer cells induced from colorectal cancer patients in vitro

Maruoka, S., Ojima, T., Iwamoto, H., Kitadani, J., Tabata, H., Tominaga, S., Katsuda, M., Hayata, K., Takeuchi, A., & Yamaue, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-07305-1 · Cited by 19 · see citing works

Isolation of endogenous cytosolic DNA from cultured cells

Mosley, S. R., & Baker, K. (2022) · STAR Protocols · doi:10.1016/j.xpro.2022.101165 · Cited by 16 · see citing works

High affinity monoclonal antibody targeting Siglec-15 for cancer immunotherapy

He, F., Wang, N., Li, J., He, L., Yang, Z., Lu, J., Xiong, G., Yu, C., & Wang, S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202106.010 · Cited by 15 · see citing works

Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens

Marks, E. I., Matera, R. M., Olszewski, A. J., Yakirevich, E., El‐Deiry, W. S., Safran, H. P., & Carneiro, B. A. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000785 · Cited by 12 · see citing works

Mutated DNA Damage Repair Pathways Are Prognostic and Chemosensitivity Markers for Resected Colorectal Cancer Liver Metastases

Wang, K., Liu, M., Wang, H., Jin, K., Yan, X., Bao, Q., Xu, D., Wang, L., Liu, W., Wang, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.643375 · Cited by 8 · see citing works

The In Vitro Differentiation of Human CD141+CLEC9A+ Dendritic Cells from Mobilized Peripheral Blood CD34+ Hematopoietic Stem Cells

Swartz, A. M., & Nair, S. K. (2022) · Current Protocols · doi:10.1002/cpz1.410 · Cited by 8 · see citing works

Mismatch repair deficiency is not sufficient to increase tumor immunogenicityPreprint

Westcott, P. M. K., Muyas, F., Smith, O. C. G., Hauck, H., Sacks, N. J., Ely, Z. A., Jaeger, A. M., Rideout, W. M., Bhutkar, A. J., Zhang, D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.24.457572 · Cited by 8 · see citing works

Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer

Kalanxhi, E., Meltzer, S., & Ree, A. H. (2020) · Cancers · doi:10.3390/cancers12082193 · Cited by 7 · see citing works

Advancements in immunotherapy for colorectal cancer treatment: a comprehensive review of strategies, challenges, and future prospective

Kaviarasan, V., Das, A., Deka, D., Saha, B., Banerjee, A., Sharma, N. R., Duttaroy, A. K., & Pathak, S. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04790-w · Cited by 45 · see citing works

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy

Nikolouzakis, T. K., Chrysos, E., Docea, A. O., Fragkiadaki, P., Souglakos, J., Tsiaoussis, J., & Tsatsakis, A. (2024) · Cancers · doi:10.3390/cancers16111995 · Cited by 37 · see citing works

The Effect of Microbiome-Derived Metabolites in Inflammation-Related Cancer Prevention and Treatment

Mafe, A. N., & Büsselberg, D. (2025) · Biomolecules · doi:10.3390/biom15050688 · Cited by 37 · see citing works

Lentinula edodes as a Source of Bioactive Compounds with Therapeutical Potential in Intestinal Inflammation and Colorectal Cancer

Bugajewski, M., Angerhoefer, N., Pączek, L., & Kaleta, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073320 · Cited by 21 · see citing works

Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

Shebbo, S., Binothman, N., Darwaish, M., Niaz, H. A., Abdulal, R. H., Borjac, J., Hashem, A. M., & Mahmoud, A. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1350208 · Cited by 20 · see citing works

The tumor microenvironment and dendritic cells: Developers of pioneering strategies in colorectal cancer immunotherapy?

Ghorbaninezhad, F., Nour, M. A., Farzam, O. R., Saeedi, H., Vanan, A. G., Bakhshivand, M., Jafarlou, M., Hatami‐Sadr, A., & Baradaran, B. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189281 · Cited by 23 · see citing works

Inhibition of Glutamate‐to‐Glutathione Flux Promotes Tumor Antigen Presentation in Colorectal Cancer Cells

Yu, T., der Jeught, K. V., Zhu, H., Zhou, Z., Sharma, S., Liu, S., Eyvani, H., So, K. M., Singh, N., Wang, J., et al. (2024) · Advanced Science · doi:10.1002/advs.202310308 · Cited by 18 · see citing works

NLRP3 activation promotes cGAS/STING signaling and antitumor immunity by colorectal cancer cells

Mowat, C., Schiller, D., & Baker, K. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04088-y · Cited by 18 · see citing works

Tumor Necrosis Factor-Alpha’s Role in the Pathophysiology of Colon Cancer

Khan, S., Aldawood, Y. O., Shaikh, A. H., Zobairi, A., Nabilah, U., Alqahtani, H. M., & Vaali‐Mohammed, M. (2025) · Diseases · doi:10.3390/diseases13060185 · Cited by 13 · see citing works

Phase 1b/2 study of BMS-813160, a CCR2/5 dual antagonist, in combination with chemotherapy or nivolumab in patients with advanced pancreatic or colorectal cancer

Le, D. T., Folprecht, G., Varghese, A. M., Gutiérrez, M., Noel, M. S., Trikalinos, N. A., Chen, E. X., Dayyani, F., Davis, S. L., Ma, W. W., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011284 · Cited by 13 · see citing works

Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review

Kciuk, M., Wanke, K., Kruczkowska, W., Marciniak, B., & Kontek, R. (2025) · Molecules · doi:10.3390/molecules30132686 · Cited by 14 · see citing works

Therapeutic Colorectal Cancer Vaccines: Emerging Modalities and Translational Opportunities

Muthukutty, P., Woo, H. Y., & Yoo, S. Y. (2025) · Vaccines · doi:10.3390/vaccines13070689 · Cited by 8 · see citing works

HIPK2 in Colon Cancer: A Potential Biomarker for Tumor Progression and Response to Therapies

Verdina, A., Garufi, A., D’Orazi, V., & D’Orazi, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25147678 · Cited by 7 · see citing works

Combined delivery of IL12 and an IL18 mutant without IL18BP-binding activity by an adenoviral vector enhances tumor specific immunity

Cheng, Y., Luo, R., & Li, E. (2025) · Scientific Reports · doi:10.1038/s41598-024-84693-6 · Cited by 7 · see citing works

The Role of MSI Testing Methodology and Its Heterogeneity in Predicting Colorectal Cancer Immunotherapy Response

Lebedeva, A., Taraskina, A. N., Grigoreva, T. V., Belova, E., Kuznetsova, O. A., Ivanilova, D., Sergeeva, A., Kavun, A., Михайлович, В. Е., Nikulin, V., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073420 · Cited by 6 · see citing works

Effect of Liver Metastases on Survival in Microsatellite-Stable Metastatic Colorectal Cancer Treated with Immune Checkpoint Inhibitors

Pakvisal, N., Pappas, L., Caughey, B. A., Horick, N., Tarazona, N., Vora, K. B., Ouyang, B., Pandey, A., Peacker, B. L., Sun, J., et al. (2026) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0690 · Cited by 4 · see citing works

Development and interpretation of a pathomics-based model for the prediction of immune therapy response in colorectal cancer

Luo, Y., Tian, Q., Xu, L., Zeng, D., Zhang, H., Zeng, T., Tang, H., Wang, C., & Chen, Y. (2025) · Methods · doi:10.1016/j.ymeth.2025.05.012 · Cited by 3 · see citing works

Associations of plasma protein levels with risk of colorectal cancer: a proteome-wide Mendelian randomization study

Pan, Z.-K., Wu, M.-H., Shi, H., Ni, Y.-J., Geng, Q.-L., & Ye, J. (2025) · Clinical Proteomics · doi:10.1186/s12014-025-09545-5 · Cited by 3 · see citing works

A tumor-selective mRNA system enables precision cancer treatment

Żak, M. M., Yoo, J., Utrero‐Rico, A., Walter, W., Mainkar, G., Adjmi, M., Kurian, A. A., Rahaman, A., Lozano‐Ojalvo, D., Ochando, J., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.11.015 · Cited by 4 · see citing works

Evaluation of blood MSI burden dynamics to trace immune checkpoint inhibitor therapy efficacy through the course of treatment

Михайлович, В. Е., Lebedeva, A., Kuznetsova, O. A., Kravchuk, D., Belova, E., Taraskina, A. E., Grigoreva, T. V., Kavun, A., Yudina, V., Belyaeva, L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-73952-1 · Cited by 3 · see citing works

SOX17 : a new therapeutic target for immune evasion of colorectal cancer

Das, A., Yilmaz, Ö. H., Yilmaz, O. H., & Deshpande, V. (2025) · Journal of Clinical Pathology · doi:10.1136/jcp-2024-209878 · Cited by 2 · see citing works

FNDC5 and ACOX1 as Biomarkers of Peroxisomal Activity with Contrast Outcomes in Colon Adenocarcinoma

Hepei, Y., Jun, Z., Muhammad, K., Baiyao, W., Hu, X., Hao, W., Wang, Z., & Yawei, Y. (2025) · Biological Procedures Online · doi:10.1186/s12575-025-00289-y · Cited by 2 · see citing works

Colorectal cancer worldwide: epidemiological trends, economic burden, and the promise of AI-driven solutions

Le, D. T. P., & Pham, T. D. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001371 · Cited by 4 · see citing works

How could γδ T cells change the treatment landscape for colorectal cancers?

Blanco-Domínguez, R., & Mensurado, S. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2572962 · Cited by 2 · see citing works

Review of carcinogenesis mechanisms and new therapeutic targets in colorectal cancer

Önol, A. B. (2025) · Developments and Experiments in Health and Medicine · doi:10.18614/dehm.1751154 · Cited by 1 · see citing works

C. difficile Infection in Colorectal Cancer: Risk Determinants, Outcomes, and Evolving Management Approaches

Abduljabbar, M., Al-Rawi, S. S. M., Midhin, B. K., Mohammadzadeh, R., Hasan, R. N., Kouhzad, M., Alanchari, N., & Rajabi, E. (2025) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01321-w · Cited by 1 · see citing works

Targeting γδ T cells for immunotherapies against colorectal cancer

Mikulak, J., Marzano, P., Cazzetta, V., & Mavilio, D. (2025) · Trends in Immunology · doi:10.1016/j.it.2025.11.009 · Cited by 1 · see citing works

Metabolic profiling of the TME uncovers the contrasting impacts of CKMT2 and PDE2A in CRC progression and therapeutic response

Fu, Y., Lai, J., Huang, K., Liu, L., & Liao, G. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1732137 · Cited by 1 · see citing works

Early-onset colorectal cancer: the importance of timely screening

Fagoonee, S., Dhasmana, A., & Chauhan, S. C. (2024) · Minerva Biotechnology and Biomolecular Research · doi:10.23736/s2724-542x.24.03156-0

Pathomics Image Analysis of Tumor Infiltrating Lymphocytes (TILs) in Colon CancerPreprint

Zhang, Y., Abousamra, S., Hasan, M., Torre-Healy, L. A., Krichevsky, S., Shrestha, S., Bremer, E., Oldridge, D. A., Rech, A. J., Furth, E. E., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6173056/v1

Integrated neoantigen and immune cell profiling of POLε-mutant colorectal tumors reveals distinct immune sub-typesPreprint

Srikakulam, N., Sukrithan, V., & Miles, W. O. (2025) · Research Square · doi:10.21203/rs.3.rs-7245242/v1

Immunotherapy in colorectal cancer

Dimitrová, E. (2025) · Scripta Scientifica Medica · doi:10.14748/dbef7r82

Decline in Circadian Robustness in Lung Cancer Patients During Immunotherapy is Associated With Increased Risk of Disease Progression and Death

Strøm, L., Amidi, A., Wu, L. M., Meldgaard, P., Ancoli‐Israel, S., Lekander, M., Mroczek, D. K., & Zachariae, R. H. (2025) · Journal of Biological Rhythms · doi:10.1177/07487304251398276

Disrupting the Immunosuppressive Myeloid Compartment in Solid Tumors

Patel, M. S., der Jeught, K. V., & Datta, J. (2026) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.10.004

Converting cold to hot: Strategies to sensitize microsatellite-stable colorectal cancer to immunotherapy

Chi, F., Liu, C.-B., Li, J., Xia, X.-W., Hua, Q.-J., & Wang, W. (2026) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v18.i5.118319

CXCR3 signaling promotes Delta One T cell recruitment and antitumor efficacy in colorectal cancer

Carreira, M., Barros, L., Cruz, R. M., Ferreira, C., Costa, C., Ferreira, C. M., Mensurado, S., Silva‐Santos, B., & Blanco-Domínguez, R. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014668

An herbal formula, SH003 alleviates colorectal cancer through dual targeting of adaptive and innate checkpoints PD-L1/CD47

Han, N., Hwang, H.-H., Kim, T., Lee, H., Yi, T., Park, H. W., Ko, S., & Moon, P. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04338-8

siRNA–polymer conjugates for the delivery of RNAi therapeutics for the treatment of colon cancer

Belavadi, S., Paul, S., Kadiri, S. K., & Tiwari, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40443-6.00013-1

An ICD gene set-derived immune contexture signature for colorectal cancer prognosis: integrated single-cell and bulk transcriptomic analysis with external validation

Su, S., Chen, G., Yang, S., 刘爱群, Huang, J., & Yang, B. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2026.101389

Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival

Zhang, Y., Guan, H., Feng, X., Liu, M., Shao, J., Liu, M., He, J., Jin, Y., Zhu, J., & Zheng, C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1616414 · Cited by 8 · see citing works

Immunotherapy in colorectal cancer: Statuses and strategies

Li, Y., Cheng, Z., Li, S., & Zhang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41354 · Cited by 19 · see citing works

Current Status and Research Progress of Immunotherapy for Colorectal Cancer

ZHANG, X., LIANG, X., & Shaozhong, W. E. I. (2024) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.3971/j.issn.1000-8578.2024.24.0008

Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

Shebbo, S., Binothman, N., Darwaish, M., Niaz, H. A., Abdulal, R. H., Borjac, J., Hashem, A. M., & Mahmoud, A. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1350208 · Cited by 20 · see citing works

Recent research progress and clinical status of immunotherapy for colorectal cancer

Huo, Z., Liu, G., & Li, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.06.089 · Cited by 23 · see citing works